4//SEC Filing
Dethlefs Sven 4
Accession 0001209191-22-017035
CIK 0000818686other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:04 PM ET
Size
22.5 KB
Accession
0001209191-22-017035
Insider Transaction Report
Form 4
Dethlefs Sven
EVP Global Marketing&Portfolio
Transactions
- Exercise/Conversion
Restricted Share Units
2022-03-05−24,952→ 74,857 total→ Ordinary Shares (24,952 underlying) - Exercise/Conversion
Ordinary Shares
2022-03-04+37,939→ 137,396 total - Exercise/Conversion
Ordinary Shares
2022-03-04+13,930→ 151,326 total - Sale
Ordinary Shares
2022-03-04$7.48/sh−3,904$29,212→ 147,422 total - Exercise/Conversion
Ordinary Shares
2022-03-05+24,952→ 172,374 total - Exercise/Conversion
Restricted Share Units
2022-03-04−13,930→ 13,931 total→ Ordinary Shares (13,930 underlying) - Award
Restricted Share Units
2022-03-04+154,155→ 154,155 total→ Ordinary Shares (154,155 underlying) - Sale
Ordinary Shares
2022-03-07$7.37/sh−6,993$51,515→ 165,381 total - Exercise/Conversion
Restricted Share Units
2022-03-04−37,939→ 0 total→ Ordinary Shares (37,939 underlying)
Footnotes (10)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F10]Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
- [F8]Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.
- [F9]Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001726010
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 4:04 PM ET
- Size
- 22.5 KB